Claritev Corporation (CTEV)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Claritev Corporation (CTEV) trades at $17.60 with AI Score 49/100 (Weak). Claritev Corporation (CTEV) provides data analytics and technology-enabled solutions to the healthcare industry. They focus on cost management, payment integrity, and revenue integrity. Market cap: 292M, Sector: Healthcare.
Last analyzed: Feb 9, 2026Claritev Corporation (CTEV) Healthcare & Pipeline Overview
Claritev Corporation (CTEV) offers data-driven solutions for healthcare cost management and revenue integrity, leveraging advanced analytics and technology to optimize benefit plan design and reduce costs for insurers and healthcare providers, positioning them as a key player in healthcare efficiency.
Investment Thesis
Claritev Corporation presents a notable research candidate within the healthcare information services sector. The company's focus on data analytics and technology-enabled cost management solutions positions it to capitalize on the growing need for efficiency and cost reduction in the healthcare industry. Despite a current negative P/E ratio of -1.25 and a profit margin of -35.9%, the company's high gross margin of 74.7% indicates strong potential for profitability with improved cost controls. Key value drivers include the increasing adoption of data analytics in healthcare, the rising demand for payment and revenue integrity solutions, and the company's ability to expand its customer base and service offerings. Upcoming catalysts include potential partnerships with major healthcare providers and the launch of new data analytics products. Given the market cap of $0.43B, CTEV offers substantial upside potential if it can execute its growth strategy and achieve profitability.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 74.7% demonstrates strong pricing power and efficient service delivery.
- Market Cap of $0.43B indicates potential for growth and value appreciation.
- Beta of 0.53 suggests lower volatility compared to the overall market.
- Serves a diverse client base including national and regional insurance companies, Blue Cross and Blue Shield plans, and TPAs.
- Focus on data analytics and technology-enabled solutions aligns with the growing demand for cost management in healthcare.
Competitors & Peers
Strengths
- Comprehensive suite of data analytics and technology-enabled solutions.
- Strong expertise in healthcare cost management and revenue integrity.
- Established relationships with a diverse client base.
- High gross margin of 74.7%.
Weaknesses
- Negative P/E ratio of -1.25.
- Negative profit margin of -35.9%.
- Reliance on the US healthcare market.
- Limited brand recognition compared to larger competitors.
Catalysts
- Potential partnerships with major healthcare providers to expand customer base.
- Increasing adoption of data analytics in the healthcare industry.
- Rising demand for payment and revenue integrity solutions.
- Launch of new data analytics products and services.
Risks
- Increasing competition from other healthcare IT companies.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturn affecting healthcare spending.
- Cybersecurity threats and data breaches.
- Inability to achieve profitability and positive cash flow.
Growth Opportunities
- Expansion of Data Analytics Services: CTEV can further expand its data analytics services by developing new solutions that address emerging needs in the healthcare industry. The market for healthcare analytics is projected to reach $75 billion by 2028, driven by the increasing adoption of data-driven decision-making in healthcare. By investing in research and development and forming strategic partnerships, CTEV can capture a larger share of this growing market. Timeline: Ongoing.
- Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with major healthcare providers can provide CTEV with access to a larger customer base and valuable data insights. These partnerships can also enable CTEV to develop customized solutions that address the specific needs of healthcare providers. The market for healthcare partnerships is estimated to be worth $20 billion annually. Timeline: Upcoming.
- Geographic Expansion: CTEV can expand its geographic reach by targeting new markets in the United States and internationally. The global healthcare IT market is projected to reach $440 billion by 2026, driven by the increasing adoption of healthcare IT solutions in developing countries. By establishing a presence in new markets, CTEV can diversify its revenue streams and reduce its reliance on the US market. Timeline: Ongoing.
- Development of New Technology Solutions: Investing in the development of new technology solutions, such as artificial intelligence and machine learning, can enable CTEV to offer more advanced and efficient services. The market for AI in healthcare is projected to reach $34 billion by 2027, driven by the increasing adoption of AI-powered solutions in healthcare. By developing new technology solutions, CTEV can differentiate itself from its competitors and attract new customers. Timeline: Ongoing.
- Acquisition of Complementary Businesses: CTEV can acquire complementary businesses to expand its service offerings and customer base. The market for healthcare acquisitions is estimated to be worth $100 billion annually. By acquiring companies with complementary capabilities, CTEV can create synergies and enhance its competitive position. Timeline: Potential.
Opportunities
- Expansion of data analytics services.
- Strategic partnerships with healthcare providers.
- Geographic expansion into new markets.
- Development of new technology solutions, such as AI and machine learning.
Threats
- Increasing competition from other healthcare IT companies.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturn affecting healthcare spending.
- Cybersecurity threats and data breaches.
Competitive Advantages
- Proprietary data analytics algorithms and technology.
- Established relationships with a diverse client base.
- Expertise in healthcare cost management and revenue integrity.
- Comprehensive suite of services covering the entire healthcare payment cycle.
About CTEV
Founded in 1980 and headquartered in New York City, Claritev Corporation (CTEV) is a leading provider of data analytics and technology-enabled solutions for the healthcare industry. Originally known as MultiPlan Corporation, the company rebranded as Claritev Corporation in February 2025, signaling a renewed focus on innovation and technology. CTEV's core business revolves around offering a suite of services designed to help healthcare organizations manage costs, ensure payment accuracy, and optimize revenue. These services include analytics-based solutions that leverage data-driven algorithms to detect claims overcharges and negotiate reimbursements, as well as network-based services that provide contracted discounts with healthcare providers. CTEV's payment and revenue integrity services focus on identifying and removing improper charges, while also working to restore underpaid premium dollars. The company's data and decision science services offer descriptive, predictive, and prescriptive analytics to improve benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care. CTEV serves a diverse range of clients, including national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. CTEV is committed to driving efficiency and value in the healthcare system through its innovative technology and data-driven insights.
What They Do
- Provides data analytics services to reduce medical costs.
- Offers technology-enabled cost management solutions.
- Delivers payment and revenue integrity services.
- Detects claims over-charges and negotiates reimbursements.
- Provides contracted discounts with healthcare providers.
- Offers outsourced network development and management services.
- Applies data science to improve clinical outcomes and reduce the total cost of care.
Business Model
- Generates revenue through fees for data analytics services.
- Earns revenue from payment and revenue integrity solutions.
- Receives fees for network-based services and contracted discounts.
- Provides data and decision science services on a subscription or project basis.
Industry Context
Claritev Corporation operates within the healthcare information services industry, a sector experiencing significant growth due to the increasing complexity of healthcare finance and the need for cost containment. The industry is characterized by a growing demand for data analytics, revenue cycle management, and payment integrity solutions. CTEV competes with other healthcare IT companies, including Axogen (AXGN), Dentsply Sirona (DNTH), Envision Healthcare (EVH), GoodRx Holdings (GDRX), and iArtisan Healthcare Acquisition Corp (IART). These companies offer various solutions, but CTEV differentiates itself through its comprehensive suite of data analytics and technology-enabled services. The market is expected to continue growing as healthcare providers and payers seek to improve efficiency and reduce costs.
Key Customers
- National and regional insurance companies
- Blue Cross and Blue Shield plans
- Provider-sponsored and independent health plans
- Third-party administrators (TPAs)
- Self-insured health plans
Financials
Chart & Info
Claritev Corporation (CTEV) stock price: $17.60 (+0.71, +4.20%)
Latest News
-
Citigroup Inc. Buys New Holdings in Claritev $CTEV
defenseworld.net · Mar 9, 2026
-
How The Claritev (CTEV) Investment Story Is Shifting As Expectations And Valuation Reset
Yahoo! Finance: CTEV News · Mar 8, 2026
-
Claritev Corporation (CTEV) Discusses Business Outlook and Addresses Investor Questions Following Recent Quarter Transcript
seekingalpha.com · Mar 6, 2026
-
Alpha Buying: Following the Insiders Into a Volatile Market
benzinga · Mar 5, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CTEV.
Price Targets
Consensus target: $33.67
MoonshotScore
What does this score mean?
The MoonshotScore rates CTEV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Citigroup Inc. Buys New Holdings in Claritev $CTEV
How The Claritev (CTEV) Investment Story Is Shifting As Expectations And Valuation Reset
Claritev Corporation (CTEV) Discusses Business Outlook and Addresses Investor Questions Following Recent Quarter Transcript
Alpha Buying: Following the Insiders Into a Volatile Market
CTEV Healthcare Stock FAQ
What does Claritev Corporation do?
Claritev Corporation provides data analytics and technology-enabled solutions to the healthcare industry, focusing on cost management, payment integrity, and revenue integrity. The company offers a suite of services, including analytics-based solutions that detect claims overcharges, network-based services that provide contracted discounts, and data and decision science services that improve benefit plan design and clinical outcomes. CTEV serves a diverse range of clients, including insurance companies, health plans, and TPAs, helping them to optimize their operations and reduce costs through data-driven insights.
Is CTEV stock worth researching?
CTEV stock presents a mixed investment profile. While the company's high gross margin of 74.7% and focus on a growing market segment are positive indicators, its negative P/E ratio of -1.25 and profit margin of -35.9% raise concerns about profitability. Investors may want to evaluate the company's growth potential, driven by increasing demand for healthcare data analytics, against the risks of competition and regulatory changes. A turnaround strategy focused on cost control and revenue growth could make CTEV a compelling investment, but it requires careful monitoring of financial performance and market trends.
What are the main risks for CTEV?
The main risks for CTEV include increasing competition from other healthcare IT companies, changes in healthcare regulations and reimbursement policies, and the potential for an economic downturn affecting healthcare spending. Cybersecurity threats and data breaches also pose a significant risk, given the sensitive nature of healthcare data. Additionally, the company's current lack of profitability and negative cash flow raise concerns about its long-term financial sustainability. Effective risk management and a clear path to profitability are crucial for CTEV to overcome these challenges.
What are the key factors to evaluate for CTEV?
Claritev Corporation (CTEV) currently holds an AI score of 49/100, indicating low score. Analysts target $33.67 (+91% from $17.60). Key strength: Comprehensive suite of data analytics and technology-enabled solutions. Primary risk to monitor: Increasing competition from other healthcare IT companies. This is not financial advice.
How frequently does CTEV data refresh on this page?
CTEV prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CTEV's recent stock price performance?
Recent price movement in Claritev Corporation (CTEV) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $33.67 implies 91% upside from here. Notable catalyst: Comprehensive suite of data analytics and technology-enabled solutions. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CTEV overvalued or undervalued right now?
Determining whether Claritev Corporation (CTEV) is overvalued or undervalued requires examining multiple metrics. Analysts target $33.67 (+91% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CTEV?
Before investing in Claritev Corporation (CTEV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited; further due diligence is recommended.